Robotics and Proteomics: A Promising Partnership for Biomarker Discovery
News Jul 23, 2009
Scientists at CLIPP (Clinical Innovation Proteomic Platform) use two of Tecan’s Freedom EVO® platforms to automate sample preparation for a biomarker discovery project based at the Hospital and Cancer Center in Dijon, France.
Dr Patrick Ducoroy leads CLIPP, and explained the role of automation in the project: “High sample numbers and throughput are of paramount importance to us in order to identify good, robust biomarkers for investigation. It is also vitally important to standardize procedures and treatment of samples and, in the early discovery phase, stringent quality control is a must. Quite simply, automation is essential to achieve all these objectives.”
“Our workstations are fully integrated with one another, maximizing automation and standardization of the sample preparation. A Freedom EVO 200 aliquots samples into 96-well microplates, then transfers these plates to a Freedom EVO 100 for protein and peptide purification, allowing us to process 96 patient samples for mass spectrometry in just one hour. Ultimately we are aiming for a thousand samples a week, and Tecan’s technology will be central to us achieving this goal. We have had very good support from Tecan, particularly in modifying the parameters of the workstations. I am sure this has helped us to achieve such excellent reproducibility of results, with the high throughput that we need.”
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE